Jefferies analyst Michael Leuchten said a deal “would be more than a head scratcher”, adding: “Given the strength of AstraZeneca’s growth and innovation profile, we are a bit perplexed by the news. Of course financial accretion can look good and maybe more cash generation would allow for more R&D.